United Health Products, Inc. (UEEC) intrinsic value & 10-year financials
United Health Products, Inc. (UEEC) has a Graham intrinsic value of $0.39 per share. At $0.05 on Oct 17, 2026, the stock trades 87% below that value. Over the last 10 fiscal years revenue shrank 26.7% a year to $0, with an average return on invested capital of 310.7%.
- Graham intrinsic value
- $0.39
- Share price (Oct 17, 2026)
- $0.05
- Price vs Graham value
- 87% below
- Market cap
- $13.3M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- -26.7%
- ROIC (10-yr avg)
- 310.7%
- Free cash flow (FY2025)
- —
UEEC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$2.7M | -$0.01 | — | — | 69.0% |
| FY2024 | $0 | -$2.0M | -$0.01 | — | — | 92.1% |
| FY2023 | $0 | -$2.6M | -$0.01 | — | — | 126.4% |
| FY2022 | $37.5K | -$1.7M | — | — | -7472.1% | 134.8% |
| FY2021 | $59 | -$30.5M | — | — | -50509550.8% | — |
| FY2020 | $643 | -$15.7M | — | -$1.4M | -2309277.0% | — |
| FY2019 | $4.9K | -$6.6M | — | — | -123688.1% | 940.2% |
| FY2018 | $45.9K | -$6.0M | — | — | -5184.2% | 851.1% |
| FY2017 | $645.7K | -$935.0K | — | — | -111.4% | 183.1% |
| FY2016 | $242.0K | -$535.7K | — | — | -213.8% | 88.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
United Health Products, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
United Health Products, Inc. has earned high returns on invested capital, averaging 66.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
United Health Products, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, United Health Products, Inc. is modeled at -26.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.39 per share.